Prolong Pharmaceuticals (United States)
- Research works
- 22 ▼ 68% vs 2013–17
- Citations
- 274 12.4 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 30% world 28%
Not ranked overall: Prolong Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Which keywords describe research at Prolong Pharmaceuticals (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Neuroprotection, Inflammation, Oxidative Stress, Apoptosis, Carbon Monoxide, Heme Oxygenase-1, Hemoglobin and Scavenger Receptor.
- Pathophysiology
- Genetic Mutations
- Antimicrobial Agents
- Thalassemia
- Pulmonary Hypertension
- Hemoglobin
- Epidemiology
- Oxidative Stress
- Inflammation
- Neuroprotection
- Apoptosis
- Carbon Monoxide
- Heme Oxygenase-1
- Scavenger Receptor
- Sickle-cell Disease
- Hematopoietic Stem Cells
- Febrile Neutropenia
- Neutropenia
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 18 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 18 words, with their numbers
- Neuroprotection5▲ 56×5 topics
- Inflammation4▲ 7.9×3 topics
- Apoptosis4▲ 45×2 topics
- Oxidative Stress4▲ 9.7×3 topics
- Carbon Monoxide4▲ 412×1 topic
- Epidemiology4▲ 4.2×7 topics
- Heme Oxygenase-14▲ 611×1 topic
- Hemoglobin4▲ 560×1 topic
- Scavenger Receptor4▲ 560×1 topic
- Pulmonary Hypertension2▲ 61×3 topics
- Sickle-cell Disease2▲ 188×1 topic
- Thalassemia2▲ 188×1 topic
- Hematopoietic Stem Cells1▲ 60×2 topics
- Antimicrobial Agents1▲ 248×1 topic
- Febrile Neutropenia1▲ 248×1 topic
- Genetic Mutations1▲ 8.7×1 topic
- Neutropenia1▲ 216×1 topic
- Pathophysiology1▲ 17×3 topics
Which research topics does Prolong Pharmaceuticals (United States) publish most on?
By volume in 2022–2025: Public Health and Environmental Issues, Educational Practices and Sociocultural Research, Heme Oxygenase-1 and Carbon Monoxide and Ophthalmology and Eye Disorders.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Public Health and Environmental Issues Health, Toxicology and Mutagenesis 0 works
- 2 Educational Practices and Sociocultural Research Education 0 works
- 3 Heme Oxygenase-1 and Carbon Monoxide Molecular Biology 0 works
- 4 Ophthalmology and Eye Disorders Pathology and Forensic Medicine 0 works
- 5 Parkinson's Disease and Spinal Disorders Neurology 0 works
- 6 Myasthenia Gravis and Thymoma Neurology 0 works
- 7 Folate and B Vitamins Research Rheumatology 0 works
- 8 Poisoning and overdose treatments Emergency Medicine 0 works
- 9 Neonatal Health and Biochemistry Pediatrics, Perinatology and Child Health 0 works
- 10 Hemoglobinopathies and Related Disorders Genetics 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Prolong Pharmaceuticals (United States)'s research output changed?
Output in 2018–2022 was 68% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in South Plainfield
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.